Metabolic syndrome contributes to an increased recurrence risk of non-metastatic colorectal cancer

// Jie You 1, * , Wen-Yue Liu 2, * , Gui-Qi Zhu 3, 4 , Ou-Chen Wang 1 , Rui-Min Ma 1 , Gui-Qian Huang 3, 5, * , Ke-Qing Shi 3, 6 , Gui-Long Guo 1 , Martin Braddock 7 , Ming-Hua Zheng 3, 6 1 Department of Oncological Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China 2 Department of Endocrinology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China 3 Department of Infection and Liver Diseases, Liver Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China 4 School of the First Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, China 5 Renji School of Wenzhou Medical University, Wenzhou, China 6 Institute of Hepatology, Wenzhou Medical University, Wenzhou, China 7 Global Medicines Development, AstraZeneca R&D, Alderley Park, United Kingdom * These authors have contributed equally to this work Correspondence to: Ming-Hua Zheng, e-mail: zhengmh@wmu.edu.cn Ou-Chen Wang, e-mail: woc099@163.com Keywords: non-metastatic colorectal cancer, metabolic syndrome, overall survival, disease-free survival, risk factor Received: March 27, 2015 Accepted: June 01, 2015 Published: June 12, 2015 ABSTRACT Objectives: Epidemiological data suggests a close link between metabolic syndrome (MetS) and non-metastatic colorectal cancer (NMCRC). However, the relationship between MetS and the outcome of NMCRC is less well understood. We aim to evaluate the impact of MetS on the prognosis in NMCRC patients. Methods: We performed a large cohort study of 1069 NMCRC patients. The Kaplan-Meier method was used to calculate the cumulative survival rate. Cox proportional hazard regression models were used to analyze the prognosis associated with MetS adjusting for clinicopathologic variables. Results: MetS was identified in 20.7% of NMCRC patients. Patients with MetS were more likely to be older, higher levels of blood glucose, triglycerides, high density lipoprotein, and uric acid than patients without MS ( P < 0.05 for all). During a mean period of 59.6 months follow-up, patients with MetS had a statistically significantly lower rate of disease-free survival (DFS) than the patients without MetS ( P = 0.014), especially local recurrence ( P = 0.040). However, there was no difference in overall survival ( P = 0.116). Multivariate analysis showed that the presence of MetS was an independent risk factor for DFS (HR = 0.733, 95%CI 0.545–0.987, P = 0.041), but not for OS ( P = 0.118). Conclusions: MetS is associated with an increased recurrence risk of NMCRC.